First In-Vivo Evaluation of Pharmaceutical Modulation of Porcine Ureteral Distensibility "Presentation" - Seyedamirvala Saadat
April 28, 2025
Seyedamirvala Saadat discusses porcine model research that identifies fasudil, a Rho-kinase inhibitor, as the most effective pharmacological agent for enhancing ureteral distensibility. This finding, supported by confirmation of therapeutically relevant serum drug concentrations comparable to human dosing, suggests fasudil could potentially improve outcomes during retrograde intrarenal surgery by facilitating safer ureteral access sheath passage.
Biography:
Seyedamirvala Saadat, Department of Urology, University of California, Irvine, Orange, CA
Seyedamirvala Saadat, Department of Urology, University of California, Irvine, Orange, CA
Read the Full Video Transcript
Seyedamirvala Saadat: Hello, everyone. My name is Seyedamirvala Saadat, and I'm a student researcher at University of California, Irvine, Department of Urology.
Today, I will be presenting our work on the first in vivo evaluation of pharmaceutical modulation of porcine ureteral distensibility. A pharmacological agent used in medical expulsive therapy may improve ureteral distensibility, facilitating the safer and more effective passage of ureteral access sheaths during retrograde intrarenal surgery.
In this in vivo porcine study, we sought to evaluate six different smooth muscle relaxants to determine their effectiveness in ureteral distensibility. 39 female swine models were randomized to orally receive a placebo, silodosin, tadalafil, verapamil, mirabegron, Rowatinex, or fasudil.
Ureters were bilaterally sized using ureteral dilators and a force sensor, before and after seven days of drug treatment under a 3.5 Newtons of force threshold. A pullback ureteroscopy was performed after each sizing to assess for any transmural ureteral injuries. Blood and urine samples were collected to assess serum drug levels and bacteria.
The mean change in dilator size was compared across treatment groups with control.
Verapamil and fasudil significantly increased ureteral diameter by 0.057 and 1.22 French size, respectively. Serum concentration analysis confirmed that the fasudil metabolite and verapamil were within the expected human therapeutic range.
In conclusion, in this in vivo swine study, a seven-day course of fasudil, a Rho-kinase inhibitor, safely increased ureteral distensibility by 1.22 French. Thank you very much.
Seyedamirvala Saadat: Hello, everyone. My name is Seyedamirvala Saadat, and I'm a student researcher at University of California, Irvine, Department of Urology.
Today, I will be presenting our work on the first in vivo evaluation of pharmaceutical modulation of porcine ureteral distensibility. A pharmacological agent used in medical expulsive therapy may improve ureteral distensibility, facilitating the safer and more effective passage of ureteral access sheaths during retrograde intrarenal surgery.
In this in vivo porcine study, we sought to evaluate six different smooth muscle relaxants to determine their effectiveness in ureteral distensibility. 39 female swine models were randomized to orally receive a placebo, silodosin, tadalafil, verapamil, mirabegron, Rowatinex, or fasudil.
Ureters were bilaterally sized using ureteral dilators and a force sensor, before and after seven days of drug treatment under a 3.5 Newtons of force threshold. A pullback ureteroscopy was performed after each sizing to assess for any transmural ureteral injuries. Blood and urine samples were collected to assess serum drug levels and bacteria.
The mean change in dilator size was compared across treatment groups with control.
Verapamil and fasudil significantly increased ureteral diameter by 0.057 and 1.22 French size, respectively. Serum concentration analysis confirmed that the fasudil metabolite and verapamil were within the expected human therapeutic range.
In conclusion, in this in vivo swine study, a seven-day course of fasudil, a Rho-kinase inhibitor, safely increased ureteral distensibility by 1.22 French. Thank you very much.